Expression of Hyaluronan Synthases (HAS1-3) and Hyaluronidases (HYAL1-2) in Serous Ovarian Carcinomas: Inverse Correlation Between HYAL1 and Hyaluronan Content

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2009 May 14

PMID 19435493

Citations 30

Authors

Timo K Nykopp

Kirsi Rilla

Reijo Sironen

Markku I Tammi

Raija H Tammi

Kirsi Hamalainen

Anna-Mari Heikkinen

Marja Komulainen

Veli-Matti Kosma

Maarit Anttila

Affiliations

Soon will be listed here.

Abstract

Background: Hyaluronan, a tumor promoting extracellular matrix polysaccharide, is elevated in malignant epithelial ovarian tumors, and associates with an unfavorable prognosis. To explore possible contributors to the accumulation of hyaluronan, we examined the expression of hyaluronan synthases (HAS1, HAS2 and HAS3) and hyaluronidases (HYAL1 and HYAL2), correlated with hyaluronidase enzyme activity hyaluronan content and HAS1-3 immunoreactivity.

Methods: Normal ovaries (n = 5) and 34 serous epithelial ovarian tumors, divided into 4 groups: malignant grades 1+2 (n = 10); malignant grade 3 (n = 10); borderline (n = 4) and benign epithelial tumors (n = 10), were analyzed for mRNA by real-time RT-PCR and compared to hyaluronidase activity, hyaluronan staining, and HAS1-3 immunoreactivity in tissue sections of the same specimens.

Results: The levels of HAS2 and HAS3 mRNA (HAS1 was low or absent), were not consistently increased in the carcinomas, and were not significantly correlated with HAS protein or hyaluronan accumulation in individual samples. Instead, the median of HYAL1 mRNA level was 69% lower in grade 3 serous ovarian cancers compared to normal ovaries (P = 0.01). The expression of HYAL1, but not HYAL2, significantly correlated with the enzymatic activity of tissue hyaluronidases (r = 0.5; P = 0.006). An inverse correlation was noted between HYAL1 mRNA and the intensity of hyaluronan staining of the corresponding tissue sections (r = -0.4; P = 0.025).

Conclusion: The results indicate that in serous epithelial ovarian malignancies HAS expression is not consistently elevated but HYAL1 expression is significantly reduced and correlates with the accumulation of hyaluronan. (233 words).

Citing Articles

Temporal characterization of hyaluronidases after peripheral nerve injury.

Kasper M, Ellenbogen B, Li Y, Schmidt C PLoS One. 2023; 18(8):e0289956.

PMID: 37616240 PMC: 10449126. DOI: 10.1371/journal.pone.0289956.

Role of Hyaluronic Acid in Selected Malignant Neoplasms in Women.

Markowska A, Antoszczak M, Markowska J, Huczynski A Biomedicines. 2023; 11(2).

PMID: 36830841 PMC: 9953106. DOI: 10.3390/biomedicines11020304.

Hyaluronic Acid as a Modern Approach in Anticancer Therapy-Review.

Michalczyk M, Humeniuk E, Adamczuk G, Korga-Plewko A Int J Mol Sci. 2023; 24(1).

PMID: 36613567 PMC: 9820514. DOI: 10.3390/ijms24010103.

The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer.

Riecks J, Parnigoni A, Gyorffy B, Kiesel L, Passi A, Vigetti D J Cancer Res Clin Oncol. 2022; 148(12):3399-3419.

PMID: 35767191 PMC: 9587083. DOI: 10.1007/s00432-022-04127-6.

Hyaluronan: Metabolism and Function.

Kobayashi T, Chanmee T, Itano N Biomolecules. 2020; 10(11).

PMID: 33171800 PMC: 7695009. DOI: 10.3390/biom10111525.

References

Bertrand P, Girard N, Duval C, dAnjou J, Chauzy C, Menard J . Increased hyaluronidase levels in breast tumor metastases. Int J Cancer. 1997; 73(3):327-31. DOI: 10.1002/(sici)1097-0215(19971104)73:3<327::aid-ijc4>3.0.co;2-1. View

Csoka A, Frost G, Stern R . The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001; 20(8):499-508. DOI: 10.1016/s0945-053x(01)00172-x. View

Bharadwaj A, Kovar J, Loughman E, Elowsky C, Oakley G, Simpson M . Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol. 2009; 174(3):1027-36. PMC: 2665762. DOI: 10.2353/ajpath.2009.080501. View

Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar V . Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res. 2008; 68(2):483-91. DOI: 10.1158/0008-5472.CAN-07-2140. View

Strobel T, Swanson L, Cannistra S . In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 1997; 57(7):1228-32. View

Tammi R, Rilla K, Pienimaki J, MACCALLUM D, Hogg M, Luukkonen M . Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J Biol Chem. 2001; 276(37):35111-22. DOI: 10.1074/jbc.M103481200. View

Sillanpaa S, Anttila M, Voutilainen K, Tammi R, Tammi M, Saarikoski S . CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res. 2003; 9(14):5318-24. View

Lokeshwar V, Cerwinka W, Lokeshwar B . HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res. 2005; 65(6):2243-50. DOI: 10.1158/0008-5472.CAN-04-2805. View

Tuhkanen H, Anttila M, Kosma V, Yla-Herttuala S, Heinonen S, Kuronen A . Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int J Cancer. 2004; 109(2):247-52. DOI: 10.1002/ijc.11733. View

10.

Liu D, Pearlman E, Diaconu E, Guo K, Mori H, Haqqi T . Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci U S A. 1996; 93(15):7832-7. PMC: 38834. DOI: 10.1073/pnas.93.15.7832. View

11.

Ghatak S, Misra S, Toole B . Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem. 2002; 277(41):38013-20. DOI: 10.1074/jbc.M202404200. View

12.

Ding Y, Tong M, Liu S, Moscow J, Tai H . NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis. 2004; 26(1):65-72. DOI: 10.1093/carcin/bgh277. View

13.

Atmuri V, Martin D, Hemming R, Gutsol A, Byers S, Sahebjam S . Hyaluronidase 3 (HYAL3) knockout mice do not display evidence of hyaluronan accumulation. Matrix Biol. 2008; 27(8):653-60. DOI: 10.1016/j.matbio.2008.07.006. View

14.

Bertrand P, Courel M, Maingonnat C, Jardin F, Tilly H, Bastard C . Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness. Int J Cancer. 2004; 113(2):207-12. DOI: 10.1002/ijc.20562. View

15.

de Kok J, Roelofs R, Giesendorf B, Pennings J, Waas E, Feuth T . Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest. 2004; 85(1):154-9. DOI: 10.1038/labinvest.3700208. View

16.

Lokeshwar V, Cerwinka W, Isoyama T, Lokeshwar B . HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res. 2005; 65(17):7782-9. DOI: 10.1158/0008-5472.CAN-05-1022. View

17.

Hiltunen E, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M . Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res. 2002; 62(22):6410-3. View

18.

Chang N, Pratt N, Heath J, Schultz L, Sleve D, Carey G . Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem. 2000; 276(5):3361-70. DOI: 10.1074/jbc.M007140200. View

19.

Gourley C, Paige A, Taylor K, Scott D, Francis N, Rush R . WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol. 2005; 26(6):1681-1689. PMC: 4166600. DOI: 10.3892/ijo.26.6.1681. View

20.

Slevin M, Krupinski J, Kumar S, Gaffney J . Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation. Lab Invest. 1998; 78(8):987-1003. View